Eli Lilly and Company (LLY-DE) Stock Split, History Data
Working capital analysis
In terms of working capital, Eli Lilly and Company maintains a healthy position.
The total current assets of the company are valued at $25727000000.
This represents a growth rate of 42.654% compared to the previous year.
Breaking down the current assets, the cash and investments are worth $2818600000, exhibiting a growth rate of 36.362% year-on-year.
The receivables, another significant portion of the current assets, are valued at $11336200000.
The year-on-year growth rate for receivables is 32.449%.
The inventory, which forms a critical part of the assets, is valued at $5772800000.
This represents a healthy year-on-year growth of 33.949%
On the liabilities side, the company's current liabilities total $27293200000.
This reflects a growth rate of 59.254% over the previous year, indicating the company's financial obligations are well under control.
2023
2022
2021
2020
2019
2018
Cash and investments
2818.60
2067.00
3818.50
3657.10
2337.50
7320.70
Receavebles
11336.20
8558.90
8127.20
6929.00
5541.50
5776.80
Inventory
5772.80
4309.70
3886.00
3980.30
3190.70
3098.10
Other
149.50
2954.10
2530.60
2871.50
2538.90
2146.50
Total Current Assets
25727.00
18034.50
18452.40
17462.10
13709.60
20549.60
Acc Payable
2598.80
1930.60
1670.60
1606.70
1405.30
1207.10
Short Term Debt
6904.50
1501.10
1538.30
8.70
1499.30
1102.20
Other Current Liab
3281.30
13706.50
3027.50
2750.30
2189.40
9174.80
Current Liabilities
27293.20
17138.20
15052.70
12481.60
11775.20
11888.10
Capital Structure
When examining the capital structure of Eli Lilly and Company, it is clear that the company manages a robust portfolio.
These earnings represent the profits that Eli Lilly and Company has chosen to reinvest in the business rather than distribute as dividends.
